• Je něco špatně v tomto záznamu ?

Basal Cell Carcinoma With Matrical Differentiation: Clinicopathologic, Immunohistochemical, and Molecular Biological Study of 22 Cases

L. Kyrpychova, RA. Carr, P. Martinek, T. Vanecek, R. Perret, M. Chottová-Dvořáková, M. Zamecnik, L. Hadravsky, M. Michal, DV. Kazakov,

. 2017 ; 41 (6) : 738-749.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030918

Basal cell carcinoma (BCC) with matrical differentiation is a fairly rare neoplasm, with about 30 cases documented mainly as isolated case reports. We studied a series of this neoplasm, including cases with an atypical matrical component, a hitherto unreported feature. Lesions coded as BCC with matrical differentiation were reviewed; 22 cases were included. Immunohistochemical studies were performed using antibodies against BerEp4, β-catenin, and epithelial membrane antigen (EMA). Molecular genetic studies using Ion AmpliSeq Cancer Hotspot Panel v2 by massively parallel sequencing on Ion Torrent PGM were performed in 2 cases with an atypical matrical component (1 was previously subjected to microdissection to sample the matrical and BCC areas separately). There were 13 male and 9 female patients, ranging in age from 41 to 89 years. Microscopically, all lesions manifested at least 2 components, a BCC area (follicular germinative differentiation) and areas with matrical differentiation. A BCC component dominated in 14 cases, whereas a matrical component dominated in 4 cases. Matrical differentiation was recognized as matrical/supramatrical cells (n=21), shadow cells (n=21), bright red trichohyaline granules (n=18), and blue-gray corneocytes (n=18). In 2 cases, matrical areas manifested cytologic atypia, and a third case exhibited an infiltrative growth pattern, with the tumor metastasizing to a lymph node. BerEP4 labeled the follicular germinative cells, whereas it was markedly reduced or negative in matrical areas. The reverse pattern was seen with β-catenin. EMA was negative in BCC areas but stained a proportion of matrical/supramatrical cells. Genetic studies revealed mutations of the following genes: CTNNB1, KIT, CDKN2A, TP53, SMAD4, ERBB4, and PTCH1, with some differences between the matrical and BCC components. It is concluded that matrical differentiation in BCC in most cases occurs as multiple foci. Rare neoplasms manifest atypia in the matrical areas. Immunohistochemical analysis for BerEP4, EMA, and β-catenin can be helpful in limited biopsy specimens. From a molecular biological prospective, BCC and matrical components appear to share some of the gene mutations but have differences in others, but this observation must be validated in a large series.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030918
003      
CZ-PrNML
005      
20171025122805.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000000841 $2 doi
035    __
$a (PubMed)28368926
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kyrpychova, Liubov $u *Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic ‡Bioptical Laboratory ∥Biomedical Center, Faculty of Medicine in Pilsen and Charles University Medical Faculty Hospital, Pilsen ¶Agel Laboratory of Pathology, Novy Jicin, Czech Republic †Department of Histopathology, Warwick Hospital, Warwick, United Kingdom §Department of Pathology, University of Nantes, Nantes, France.
245    10
$a Basal Cell Carcinoma With Matrical Differentiation: Clinicopathologic, Immunohistochemical, and Molecular Biological Study of 22 Cases / $c L. Kyrpychova, RA. Carr, P. Martinek, T. Vanecek, R. Perret, M. Chottová-Dvořáková, M. Zamecnik, L. Hadravsky, M. Michal, DV. Kazakov,
520    9_
$a Basal cell carcinoma (BCC) with matrical differentiation is a fairly rare neoplasm, with about 30 cases documented mainly as isolated case reports. We studied a series of this neoplasm, including cases with an atypical matrical component, a hitherto unreported feature. Lesions coded as BCC with matrical differentiation were reviewed; 22 cases were included. Immunohistochemical studies were performed using antibodies against BerEp4, β-catenin, and epithelial membrane antigen (EMA). Molecular genetic studies using Ion AmpliSeq Cancer Hotspot Panel v2 by massively parallel sequencing on Ion Torrent PGM were performed in 2 cases with an atypical matrical component (1 was previously subjected to microdissection to sample the matrical and BCC areas separately). There were 13 male and 9 female patients, ranging in age from 41 to 89 years. Microscopically, all lesions manifested at least 2 components, a BCC area (follicular germinative differentiation) and areas with matrical differentiation. A BCC component dominated in 14 cases, whereas a matrical component dominated in 4 cases. Matrical differentiation was recognized as matrical/supramatrical cells (n=21), shadow cells (n=21), bright red trichohyaline granules (n=18), and blue-gray corneocytes (n=18). In 2 cases, matrical areas manifested cytologic atypia, and a third case exhibited an infiltrative growth pattern, with the tumor metastasizing to a lymph node. BerEP4 labeled the follicular germinative cells, whereas it was markedly reduced or negative in matrical areas. The reverse pattern was seen with β-catenin. EMA was negative in BCC areas but stained a proportion of matrical/supramatrical cells. Genetic studies revealed mutations of the following genes: CTNNB1, KIT, CDKN2A, TP53, SMAD4, ERBB4, and PTCH1, with some differences between the matrical and BCC components. It is concluded that matrical differentiation in BCC in most cases occurs as multiple foci. Rare neoplasms manifest atypia in the matrical areas. Immunohistochemical analysis for BerEP4, EMA, and β-catenin can be helpful in limited biopsy specimens. From a molecular biological prospective, BCC and matrical components appear to share some of the gene mutations but have differences in others, but this observation must be validated in a large series.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a bazocelulární karcinom $x genetika $x metabolismus $x mortalita $x patologie $7 D002280
650    _2
$a buněčná diferenciace $7 D002454
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a nemoci vlasů $x genetika $x metabolismus $x mortalita $x patologie $7 D006201
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a pilomatrixom $x genetika $x metabolismus $x mortalita $x patologie $7 D018296
650    _2
$a prognóza $7 D011379
650    _2
$a nádory kůže $x genetika $x metabolismus $x mortalita $x patologie $7 D012878
655    _2
$a časopisecké články $7 D016428
700    1_
$a Carr, Richard A
700    1_
$a Martinek, Petr
700    1_
$a Vanecek, Tomas
700    1_
$a Perret, Raul
700    1_
$a Chottová-Dvořáková, Magdalena
700    1_
$a Zamecnik, Michal
700    1_
$a Hadravsky, Ladislav
700    1_
$a Michal, Michal
700    1_
$a Kazakov, Dmitry V
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 41, č. 6 (2017), s. 738-749
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28368926 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025122847 $b ABA008
999    __
$a ok $b bmc $g 1254511 $s 991945
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 41 $c 6 $d 738-749 $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...